Bendamustine in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma

References

• Hallek M, Fingerle-Rowson G, Fink A et al. Immunochemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival of previously untreated subjects with advanced chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts)112, 325 (2008).
   Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Morrison VA et al. Randomized Phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from cancer and leukemia group B 9712 (CALGB 9712). Blood101, 6–14 (2003).
   PubMed Web of Science ®Google Scholar
• Van Oers MH, Klasa R, Marcus RE et al. Rituximab maintenance improves clinical outcome of relapsed/refractory follicular non-Hodgkin’s lymphoma in patients with and without rituximab during induction: results of a prospective randomized Phase III intergroup trial. Blood108, 3295–3301 (2006).
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol.7, 379–391 (2006).
   PubMed Web of Science ®Google Scholar
• Ozegowski W, Krebs D. IMET 3393, (-[1-methyl-5-bis-(2-chloroethyl)-amino-benzimidazolyl-(2)]-butyric acid hydrochloride, a new cytostatic agent from among the series of benzimidazole mustard compounds. Zbl. Pharm.110, 1013–1019 (1971).
   Google Scholar
• Hartmann M, Zimmer C. Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393, and 3943. Biochem. Biophys. Acta287, 386–389 (1972).
   PubMed Web of Science ®Google Scholar
• Leoni LM, Bailey B, Reifert J et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin. Cancer Res.14, 309–317 (2008).
   PubMed Web of Science ®Google Scholar
• Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs7, 415–421 (1996).
   PubMed Web of Science ®Google Scholar
• Weide R. Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma. Ther. Clin. Risk Manag.4, 1–6 (2008).
   PubMedGoogle Scholar
• Kath R, Blumenstengel K, Fricke HJ et al. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J. Cancer Res. Clin. Oncol.127, 48–54 (2001).
   PubMed Web of Science ®Google Scholar
• Aivado M, Schulte K, Henze L et al. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin. Oncol.29, 19–22 (2002).
   PubMed Web of Science ®Google Scholar
• Bergmann MA, Goebeler ME, Herold M et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a Phase I/II study of the German CLL Study Group. Haematologica90, 1357–1364 (2005).
   PubMed Web of Science ®Google Scholar
• Lissitchkov T, Arnaudov G, Peytchev D et al. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCL in pre-treated patients with B-lymphocytic leukaemia (Binet stages B and C) requiring therapy. J. Cancer Res. Clin. Oncol.132, 99–104 (2006).
   PubMed Web of Science ®Google Scholar
• Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pretreated low-grade non-Hodgkin’s lymphomas. J. Cancer Res. Clin. Oncol.128, 603–609 (2002).
   PubMed Web of Science ®Google Scholar
• Niederle N, Balleisen L, Heit W et al. Bendamustine versus fludarabine as second-line treatment for subjects with chronic lymphocytic leukemia – first interim results of a randomized study. Ann. Oncol.19, 379 (2008).
   Web of Science ®Google Scholar
• Koppler H, Heymanns J, Pandorf A et al. Bendamustine plus mitoxantrone – a new effective treatment for advanced chronic lymphocytic leukaemia: results of a Phase I/II study. Leuk. Lymphoma45, 911–913 (2004).
   PubMed Web of Science ®Google Scholar
• Weide R, Pandorf A, Heymanns J et al. Bendamustine/mitoxantrone/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final report of a pilot study. Leuk. Lymphoma45, 2445–2449 (2004).
   PubMed Web of Science ®Google Scholar
• Fischer K, Stilgenbauer S, Schweighofer CD et al. Bendamustine in combination with rituximab for subjects with relapsed chronic lymphocytic leukemia: a multicentre Phase II trial of the German CLL Study Group (GCLLSG). Blood112, 128, 330 (2008).
   PubMedGoogle Scholar
• Fischer K, Cramer P, Stilgenbauer S et al. Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: a multicenter Phase II trial of the German CLL Study Group (GCLLSG). Blood (ASH Annual Meeting Abstracts)114 (2009) (Abstract 205).
   Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A et al. Bendamustine versus chlorambucil in B-cell chronic lymphocytic leukemia (CLL): an updated analysis from an international Phase III study. Blood (ASH Annual Meeting Abstracts)112 (2008) (Abstract 2091).
   Google Scholar
• Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin’s lymphomas. Anticancer Drugs12, 725–729 (2001).
   PubMed Web of Science ®Google Scholar
• Weidmann E, Kim SZ, Rost A et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin’s lymphoma. Ann. Oncol.13, 1285–1289 (2002).
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Cohen P, Chen L et al. Bendamustine in patients with rituximab-refractory and alkylator-refractory, indolent, and transformed non-Hodgkin’s lymphoma: results from a Phase II multicenter single-agent study. J. Clin. Oncol.26, 204–210 (2008).
   PubMed Web of Science ®Google Scholar
• Kahl B, Bartlett NL, Leonard JP et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin’s lymphoma: results from a multicenter study. Cancer116, 106–114 (2010).
   PubMed Web of Science ®Google Scholar
• Cheson B, Friedberg J, Kahl B et al. Bendamustine produces durable responses with an acceptable long-term safety profile in patients with rituximab-refractory non-Hodgkin’s lymphoma: a pooled analysis. Blood (ASH Annual Meeting Abstracts)114 (2009) (Abstract 2681).
   Google Scholar
• Ogura M, Uchida T, Ando K et al. Bendamustine is highly effective for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: final results of a Japanese multicenter Phase II study. Blood (ASH Annual Meeting Abstracts)114 (2009) (Abstract 3694).
   Google Scholar
• Koenigsmann M, Knauf WU, Herold M et al. Fludarabine and bendamustine in refractory and relapsed indolent lymphoma: a multicenter Phase I/II trial of the East German Society of Hematology and Oncology (OSHO). Leuk. Lymphoma45, 1821–1827 (2004).
   PubMed Web of Science ®Google Scholar
• Rummel M, Al-Batran S, Kim S et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J. Clin. Oncol.23, 3383–3389 (2005).
   PubMed Web of Science ®Google Scholar
• Robinson K, Williams M, van der Jagt R et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle-cell non-Hodgkin’s lymphoma. J. Clin. Oncol.26, 4473–4479 (2008).
   PubMed Web of Science ®Google Scholar
• Weide R, Hess G, Koppler H et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle-cell lymphomas: a multicenter Phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk. Lymphoma48, 1299–1306 (2007).
   PubMed Web of Science ®Google Scholar
• Friedberg J, Vose J, Kelly J et al. Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a multicenter Phase II clinical trial. Blood (ASH Annual Meeting Abstracts)114 (2009) (Abstract 924).
   Google Scholar
• Fowler N, Kahl B, Rosen P et al. Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study. Blood (ASH Annual Meeting Abstracts)114 (2009) (Abstract 933).
   Google Scholar
• Herold M, Schulze A, Niederwieser D et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle-cell lymphoma: results of a randomised Phase III trial (OSHO#19). J. Cancer Res. Clin. Oncol.132, 105–112 (2006).
   PubMed Web of Science ®Google Scholar
• Rummel M, Niederle N, Maschmeyer G et al. Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: final results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts)114 (2009) (Abstract 405).
   Google Scholar
• Cheson B, Kroll M. Bendamustine induced neurotoxicity. Clin. Adv. Hematol. Oncol.11, 743–746 (2009).
   Google Scholar
• Cheson B, Wendtner C, Pieper A et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, and multiple myeloma: treatment recommendations from an international consensus panel. Clin. Lymphoma Myeloma Leuk.10, 21–27 (2010).
   PubMed Web of Science ®Google Scholar
• Moskowitz A, Hamlin P Jr, Gerecitano J et al. Bendamustine Is Highly Active in Heavily Pre-Treated Relapsed and Refractory Hodgkin Lymphoma and Serves as a Bridge to Allogeneic Stem Cell Transplant. Blood (ASH Annual Meeting Abstracts)114 (2009) (Abstract 720).
   Google Scholar